DrugPatentWatch Database Preview
Twi Pharms Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for TWI PHARMS, and what generic and branded alternatives to TWI PHARMS drugs are available?
TWI PHARMS has seventeen approved drugs.
There are two tentative approvals on TWI PHARMS drugs.
Summary for Twi Pharms
| US Patents: | 0 |
| Tradenames: | 17 |
| Ingredients: | 17 |
| NDAs: | 17 |
Drugs and US Patents for Twi Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twi Pharms | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 207206-003 | Dec 19, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Twi Pharms | LABETALOL HYDROCHLORIDE | labetalol hydrochloride | TABLET;ORAL | 209603-001 | Jun 20, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Twi Pharms | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 205231-005 | Aug 30, 2018 | AB3 | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
